Amgen Stock Surges on Positive Sjögren’s Trial Results
Amgen's stock surged 4% in premarket trading on Tuesday following positive results from its Phase 3 trial of dazodalibep for Sjögren’s disease.
The OASIZ 301 study met its primary endpoint, showing significant improvement in systemic disease activity at Week 48, as measured by the EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI).
Improvements were observed as early as Week 4 and sustained through Week 48. The trial enrolled approximately 621 patients with moderate-to-severe systemic disease activity.
The most common adverse events included nasopharyngitis, urinary tract infection, hypertension, and infusion-related reactions, which were generally mild to moderate.
Amgen plans to present detailed data from the study at an upcoming medical meeting. The company's Phase 3 OASIZ 303 study of dazodalibep is expected to complete in the fourth quarter of 2026.